Friday, August 30, 2013

CDC Emerging Infectious Diseases: R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses

Volume 19, Number 9—September 2013



Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.

Katrina Sleeman1, Zhu Guo1, John Barnes, Michael Shaw, James Stevens, and Larisa V. GubarevaComments to Author 
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA 

No comments: